文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Disrupting bile acid metabolism by suppressing Fxr causes hepatocellular carcinoma induced by YAP activation.

作者信息

Liu Yuchen, Zhu Juanjuan, Jin Yu, Sun Zhonghe, Wu Xiaolin, Zhou Huiping, Yang Yingzi

机构信息

Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA, USA.

Cancer Research Technology Program, Frederick National Laboratory for Cancer, Frederick, MD, USA.

出版信息

Nat Commun. 2025 Apr 15;16(1):3583. doi: 10.1038/s41467-025-58809-z.


DOI:10.1038/s41467-025-58809-z
PMID:40234449
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12000370/
Abstract

Disruption of bile acid (BA) metabolism causes various liver diseases including hepatocellular carcinoma (HCC). However, the underlying molecular mechanism remains elusive. Here, we report that BA metabolism is directly controlled by a repressor function of YAP, which induces cholestasis by altering BA levels and composition via inhibiting the transcription activity of Fxr, a key physiological BA sensor. Elevated BA levels further activate hepatic YAP, resulting in a feedforward cycle leading to HCC. Mechanistically, Teads are found to bind Fxr in a DNA-binding-independent manner and recruit YAP to epigenetically suppress Fxr. Promoting BA excretion, or alleviating YAP repressor function by pharmacologically activating Fxr and inhibiting HDAC1, or overexpressing an Fxr target gene Bsep to promote BA exportation, alleviate cholestasis and HCC caused by YAP activation. Our results identify YAP's transcriptional repressor role in BA metabolism as a key driver of HCC and suggest its potential as a therapeutic target.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/7bb8120353ce/41467_2025_58809_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/e6c6aedc5909/41467_2025_58809_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/aefa803bffcf/41467_2025_58809_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/f5ae9432afba/41467_2025_58809_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/d301b25736a3/41467_2025_58809_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/46f5c26aa1e6/41467_2025_58809_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/e38878b55b5c/41467_2025_58809_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/cb4c0d75fa60/41467_2025_58809_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/11b58aa573cf/41467_2025_58809_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/7bb8120353ce/41467_2025_58809_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/e6c6aedc5909/41467_2025_58809_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/aefa803bffcf/41467_2025_58809_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/f5ae9432afba/41467_2025_58809_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/d301b25736a3/41467_2025_58809_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/46f5c26aa1e6/41467_2025_58809_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/e38878b55b5c/41467_2025_58809_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/cb4c0d75fa60/41467_2025_58809_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/11b58aa573cf/41467_2025_58809_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5c7/12000370/7bb8120353ce/41467_2025_58809_Fig9_HTML.jpg

相似文献

[1]
Disrupting bile acid metabolism by suppressing Fxr causes hepatocellular carcinoma induced by YAP activation.

Nat Commun. 2025-4-15

[2]
Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma.

Hepatology. 2013-2-15

[3]
Pharmacologic activation of hepatic farnesoid X receptor prevents parenteral nutrition-associated cholestasis in mice.

Hepatology. 2022-2

[4]
MicroRNA-210 Promotes Bile Acid-Induced Cholestatic Liver Injury by Targeting Mixed-Lineage Leukemia-4 Methyltransferase in Mice.

Hepatology. 2020-6

[5]
BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.

JCI Insight. 2020-12-8

[6]
Disordered farnesoid X receptor signaling is associated with liver carcinogenesis in Abcb11-deficient mice.

J Pathol. 2021-12

[7]
Bile acids activate YAP to promote liver carcinogenesis.

Cell Rep. 2013-11-21

[8]
Picroside II protects against cholestatic liver injury possibly through activation of farnesoid X receptor.

Phytomedicine. 2019-12-16

[9]
Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway.

J Ethnopharmacol. 2024-8-10

[10]
Farnesoid X Receptor: Effective alleviation of rifampicin -induced liver injury.

Int Immunopharmacol. 2024-9-30

本文引用的文献

[1]
Divergent WNT signaling and drug sensitivity profiles within hepatoblastoma tumors and organoids.

Nat Commun. 2024-11-20

[2]
Generation and characterization of mature hepatocyte organoids for liver metabolic studies.

J Cell Sci. 2024-5-15

[3]
Bile acid-mediated signaling in cholestatic liver diseases.

Cell Biosci. 2023-4-29

[4]
Decoding YAP dependent transcription in the liver.

Nucleic Acids Res. 2022-8-12

[5]
Development of an improved inhibitor of Lats kinases to promote regeneration of mammalian organs.

Proc Natl Acad Sci U S A. 2022-7-12

[6]
YAP induces an oncogenic transcriptional program through TET1-mediated epigenetic remodeling in liver growth and tumorigenesis.

Nat Genet. 2022-8

[7]
YAP inhibits ERα and ER breast cancer growth by disrupting a TEAD-ERα signaling axis.

Nat Commun. 2022-6-2

[8]
Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER breast cancer.

Nat Commun. 2022-2-25

[9]
Hippo signalling in the liver: role in development, regeneration and disease.

Nat Rev Gastroenterol Hepatol. 2022-5

[10]
Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis.

J Hepatol. 2022-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索